Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Getting a diagnosis

Reviewed as evidence on: Sedative/antipsychotic/mind-altering prescribing and falls, confusion, hospitalisation in dementia 4 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Risk, prevention and care in population studies

Plain-language summary

Importance Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no treatment or an alternative psychotropic is unclear. Objective To determine the absolute mortality risk increase and number needed to harm (NNH) (ie, number of patients who receive treatment that would be associated with 1 death) of antipsychotic, valproic acid and its derivatives, and antidepressant use in patients with dementia relative to either no treatment or antidepressant treatment. Design, setting, and participants A retrospective case-control study was conducted in the Veterans Health Administration from October 1, 1998, through September 30, 2009. Participants included 90,786 patients 65 years or older with a diagnosis of dementia. Final analyses were conducted in August 2014. Exposures A new prescription for an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an antidepressant (46,008 medication users). Main outcomes and measures Absolute change in mortality risk and NNH over 180 days of follow-up in medication users compared with nonmedication users matched on several risk factors. Among patients in whom a treatment with medication was initiated, mortality risk associated with each agent was also compared using the antidepressant group as the reference, adjusting for age, sex, years with dementia, presence of delirium, and other clinical and demographic characteristics. Secondary analyses compared dose-adjusted absolute change in mortality risk for olanzapine, quetiapine, and risperidone. Results Compared with respective matched nonusers, individuals receiving haloperidol had an increased mortality risk of 3.8% (95% CI, 1.0%-6.6%; P Conclusions and relevance The absolute effect of antipsychotics on mortality in elderly patients with dementia may be higher than previously reported and increases with dose.

What this study adds

Evidence grade: Moderate

This is a case-control study of 90,786 participants. In 90,786 veterans aged 65 or older with dementia, this study set out to measure how much a new prescription for an antipsychotic changes the absolute risk of death over 180 days. Reported effect size: 3.8%; 1.0%; 6.6%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Maust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., et al. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA psychiatry. https://doi.org/10.1001/jamapsychiatry.2014.3018

Vancouver

Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA psychiatry. 2015. doi:10.1001/jamapsychiatry.2014.3018. PMID: 25786075.

BibTeX

@article{maust2015-25786075,
  author  = {Maust, D. T. and Kim, H. M. and Seyfried, L. S. and Chiang, C. and Kavanagh, J. and Schneider, L. S. and Kales, H. C.},
  title   = {{Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm}},
  journal = {JAMA psychiatry},
  year    = {2015},
  doi     = {10.1001/jamapsychiatry.2014.3018},
  pmid    = {25786075},
  url     = {https://doi.org/10.1001/jamapsychiatry.2014.3018}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In 90,786 veterans aged 65 or older with dementia, this study set out to measure how much a new prescription for an antipsychotic changes the absolute risk of death over 180 days. For haloperidol, death risk was 3.8 percentage points higher than in matched people not taking the drug (95% CI 1.0–6.6), and the authors conclude the absolute effect of antipsychotics "may be higher than previously reported and increases with dose." This is an observational association, not proof of cause, and it is a reason to discuss risks and alternatives with the prescriber, not to stop a medication without advice.

Study details

How this study scored 71/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 6 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 71 of 100.71 of 100 points earned29 not earned

Published in a leading specialty journal, and it is a case-control study. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA psychiatry)
Journal's citation record 3 / 4 JAMA Psychiatry: journal h-index 256 (OpenAlex, 2026-10-29)
Study design 6 / 12 A case-control study
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 4 / 4 90,786 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 610 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 46.9 citations a year over 13 year(s) since 2015
Impact for its field and year 5 / 6 Cited 34.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 20 other studies in this library
Still being cited 3 / 4 Cited 109 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Helen C. Kales: h-index 55 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Michigan: institution h-index 2,240 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 25786075)
Free to read 0 / 2 Behind a paywall — scores zero
Total 71 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

20 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “sedative-antipsychotic-harm-in-dementia”

4 studies in the library carry the topic tag “sedative-antipsychotic-harm-in-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →